Clinical trials: Iris Tumor, open to volunteers
Metastatic Gastric Adenocarcinoma, Second Line
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
Primary Objectives In phase 1b cohort, to determine MTD (maximum tolerated dose) of nal-IRI (ONIVYDE®) in combination with Ramucirumab (Cyramza®) and TAS-102 (LONSURF®) In phase II cohort, to evaluate disease objective response…
- Conditions
- Metastatic Gastric Adenocarcinoma, Second Line, Chemotherapy
- Trial name
- NCT05927857
- Testing
- nal-IRI /Experimental, Ramucirumab /Experimental, Trifluridine/Tipiracil /Experimental
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- National Health Research Institutes, Taiwan
Any Advanced Solid Tumors
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the…
- Trial name
- IRIS (NCT07836101)
- Testing
- Sarilumab, ICI Therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Intellectual Disability, Neurodevelopmental Disorders
Physical Activity and Community EmPOWERment Project
Purpose: Conduct a wait-list randomized controlled trial (RCT) of an inclusive physical activity program called PACE for adults with intellectual disability (ID) who are not yet showing signs of Alzheimer's Disease…
- Conditions
- Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome
- Trial name
- PACE (NCT06740162)
- Testing
- PACE Program
- Where
- 2 sites in United States
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Breast Cancer
IRIS: Risk-Based Imaging After Breast-Conserving Surgery
Breast cancer follow-up after curative treatment is currently based on largely uniform imaging surveillance strategies, despite substantial variation in recurrence risk across patient subgroups.
- Trial name
- IRIS (NCT07426510)
- Testing
- Risk-Stratified Imaging Surveillance, Standard Mammographic Surveillance
- Volunteers
- 2,300 people
- Sponsor
- Umeå University
Iris Tumor
Observational Study of Iris Tumors
This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions.
- Trial name
- NCT03809585
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Colon Cancer, Rectal Cancer
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as…
- Trial name
- SCOTI (NCT05806931)
- Testing
- TAS-102, oxaliplatin, irinotecan with bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Advanced Solid Malignancies
Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies
Phase I trial, Multiple centers, open-label, non-randomized single-arm study
- Trial name
- ICONIC (NCT07782346)
- Testing
- Liposomal Irinotecan Plus Cisplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- National Health Research Institutes, Taiwan
GEP-NET
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
The current study is an investigator-initiated, single-arm phase 1/2 study that enrolled patients with advanced or recurrent and/or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma for the…
- Trial name
- NCT05385861
- Testing
- nanoliposomal irinotecan plus carboplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 52 people
- Sponsor
- National Health Research Institutes, Taiwan
Rectal Cancer Patients
Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer
This study is for adults with locally advanced rectal cancer that has not spread to distant organs, and is classified as pMMR or MSS (which means it typically does not respond well to immunotherapy alone).
- Trial name
- NCT07521605
- Testing
- Short-Course Radiotherapy, Liposomal Irinotecan (nal-IRI), Capecitabine
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Guangdong Provincial People's Hospital
Surgery, Liver Metastases
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
The aim of the study is to investigate if iv iron formulation improve recovery after surgery with blood loss. Post-operative anaemia is a common debilitating condition after major surgery due to a combination of preoperative iron…
- Conditions
- Surgery, Liver Metastases, Liver Cancer, Pancreas Cancer
- Trial name
- IRIS (NCT05744219)
- Testing
- Ferric carboxymaltose
- Where
- Sweden
- Volunteers
- 338 people
- Sponsor
- Jon Unosson
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Advanced Metastatic Pancreatic Cancer
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
This study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator. The indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after…
- Trial name
- NCT06662006
- Testing
- nal-IRI,5-fu,LV, benmelstobart, anlotinib
- Where
- China
- Volunteers
- 56 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Advanced Small Intestine Cancer, Appendiceal Cancers
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
This study will evaluate the safety and efficacy of NALIRIFOX per NAPOLI-3 regimen as first-line chemotherapy for patients with advanced small intestine and appendiceal cancers.
- Trial name
- NCT07060014
- Testing
- Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- The Methodist Hospital Research Institute
Colorectal Cancer
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
This is a multi-center, single-arm study to investigate the efficacy and safety of liposomal irinotecan+5-FU/LV+ bevacizumab as second-line therapy in metastatic colorectal cancer in Chinese population.
- Trial name
- NCT06184698
- Testing
- liposomal irinotecan, 5-FU, LV
- Where
- China
- Volunteers
- 173 people
- Sponsor
- Hebei Medical University Fourth Hospital